Purpose: Benzotriazine-N-oxide bioreductive prodrugs such as tirapazamine and its improved analogue CEN-209 (SN30000) have potential for exploiting hypoxia in tumors. Here, we test the hypothesis that the 2-nitroimidazole EF5, in clinical development for both immunohistochemical and positron emission tomography imaging of hypoxia, can detect not only hypoxia but also the one-electron reductases required for activation of these hypoxia-targeted prodrugs.
Introduction
The disorganized microvasculature of tumors often gives rise to severe hypoxia, which is an attractive therapeutic target in oncology (1) . The potential for exploiting hypoxia as a target is reinforced by its association with multiple overlapping aspects of tumor progression, including proliferation (2), invasiveness and metastasis (3), angiogenesis and vasculogenesis (4), resistance to cell death (5), the metabolic switch to aerobic glycolysis (6) , and genomic instability (7) . In addition, hypoxic cells are radioresistant and also often resistant to cytotoxic chemotherapy through multiple mechanisms (1) . Despite these compelling reasons for targeting hypoxia, and although some hypoxia-targeting approaches have been tested in clinical trials (1) , no drugs that exploit tumor hypoxia are approved for clinical use as yet.
The most intensively studied and clinically most advanced (although recently terminated) hypoxia-targeting agent is the benzotriazine di-N-oxide tirapazamine (TPZ), which is a bioreductive prodrug that is metabolized by oneelectron reductases [such as NADPH:cytochrome P450 oxidoreductase (CYPOR)] in the absence of oxygen to generate a DNA-reactive cytotoxin (8, 9) . Hypoxic selectivity results from the reoxidation of the initial free radical reduction product by molecular oxygen; in the absence of oxygen, the TPZ free radical lives long enough to spontaneously decompose to powerful oxidizing radicals (10) which induce complex DNA damage, DNA replication fork arrest, and cytotoxicity (11, 12) .
Although TPZ shows marked (50-to 200-fold) selectivity for hypoxic cells in culture (8) , its selectivity in tumors is significantly compromised by inefficient penetration into hypoxic tissue (13, 14) . We have recently reported (15) an analogue of TPZ, CEN-209 (SN30000; see Fig. 2A for structure) with improved tissue penetration because of a higher tissue diffusion coefficient (a consequence of higher lipophilicity and removal of the hydrogen bonding 3-amino moiety of TPZ). The 3-alkyl substituent also raises the reduction potential and rate of bioreductive metabolism of CEN-209, leading to higher hypoxic potency and selectivity in culture (15) . These features are together presumably responsible for the improved therapeutic activity of CEN-209 relative to TPZ against hypoxic (radioresistant) cells in human tumor xenografts (15) and have led to its selection for clinical development.
In addition to its limited penetration into hypoxic tissue, clinical development of TPZ has been frustrated by the lack of prospective assessment of hypoxia in these studies. Given the marked variability in hypoxia between individual tumors (16) , the failure to identify the patient subpopulation carrying the target in randomized phase III clinical trials of TPZ (9, 17) can be expected to have seriously compromised outcomes. One substudy linked to a randomized phase II trial pointed the way forward by showing a strong association between the presence of hypoxia and clinical activity of TPZ in combination with chemoradiation for advanced head and neck squamous cell carcinomas (HNSCC; ref. 18 ). This emphasizes the critical need for assessment of hypoxia as a stratification biomarker for CEN-209, as for other bioreductive prodrugs and other hypoxiatargeting approaches.
The above-mentioned assessment of hypoxia in HNSCC (18) used PET imaging with a 2-nitroimidazole probe, [ 18 F]-fluoromisonidazole, which is metabolized by bioreduction under hypoxia to form intracellular radiolabeled products that are retained by cells (largely through covalent binding to proteins; ref. 19) . A related hypoxia probe, [ 18 F]-FAZA, has been shown to identify tumors responsive to TPZ in a preclinical study (20) . Several other 2-nitroimidazole probes are also in clinical development for imaging hypoxia (21) (22) (23) , including [ 18 F]-EF5 [(N-(2,2,3,3,3-pentafluoropropyl-2-(2-nitroimidazolyl)-acetamide)); ref. 24, 25] , which has the useful additional feature that protein adducts generated by hypoxic bioreduction can be detected by immunostaining (25) (26) (27) . In this study, we test the hypothesis that reduction of EF5 depends on the same one-electron reductases that activate CEN-209 under hypoxia, in which case EF5 would have the potential to act as a dual reporter of reductase activity as well as hypoxia in human tumors. We show that both CEN-209 and EF5 are substrates for CYPOR, which is a known one-electron reductase for several bioreductive prodrugs (28) (29) (30) (31) and simple 2-nitroimidazoles (32) . Furthermore, we show that reductive activation of CEN-209 is more strongly correlated with EF5 binding than CYPOR activity, suggesting that EF5 detects additional CEN-209 reductases, and thus that EF5 has the potential to identify not only hypoxia but also expression of the oxidoreductases required for activation of CEN-209.
Materials and Methods

Chemical compounds
CEN-209 (SN30000), SN30672 (the 1-oxide metabolite of CEN-209), SN33093 (nor-oxide of CEN-209), TPZ, SR4317 (1-oxide of TPZ), SR4330 (nor-oxide of TPZ), and SN29751 were synthesized as previously described (15) . Stock solutions (20 mmol/L) in dimethyl sulfoxide were stored at À80 C and working solutions made by dilution into culture medium. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-labeled EF5 (33) was kindly supplied by Dr. C.J. Koch (University of Pennsylvania, Philadelphia, PA) and purified by semipreparative high-performance liquid chromatography (HPLC) to a final specific activity of 4.59 Â 10 5 Bq/mmol. Internal standards for quantifying CEN-209 and its metabolites by mass spectrometry were the corresponding octadeuterated compounds (SN30000.8D, SN30672.8D, and SN33093.8D), which were synthesized as described in Supplementary Methods. The internal standards used for TPZ and its metabolites were the corresponding 8-methoxy derivatives, synthesized as previously (34) . All other chemicals were purchased from Sigma-Aldrich, except nonradiolabeled EF5 which was a gift from National Cancer Institute.
Cell culture
Origins of all wild-type cell lines (used within 3 months of passage from authenticated frozen stocks) and culture conditions are reported elsewhere (35 (35) , using a derivative of pIRES-P (37) with a CMV immediate early promoter and
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used for xenograft studies. The CYPOR-overexpressing lines were maintained in medium containing 3 mmol/L puromycin. All cell lines were confirmed to be free of Mycoplasma by PCR-ELISA (Roche Diagnostics).
Clonogenic assay
Cells in log-phase growth were harvested by trypsinization, and stirred cell suspensions [10 6 cells/mL in aMEM with 5% fetal calf serum (FCS)] were exposed to drugs under flowing 5% CO 2 in air or N 2 as previously described (13) . After 1 hour drug exposure, cells were washed with drugfree medium by centrifugation and up to 10 5 cells/P60 dish were plated to determine clonogenic survival. The dishes were incubated at 37 C for 14 days, stained with methylene blue (2 g/L in 50% aqueous ethanol), and colonies with more than 50 cells were counted.
Xenograft models and treatments
All animal studies were approved by the University of Auckland Animal Ethics Committee. ) at atmospheric pressure for 90 or 120 minutes at a flow rate of 110 L/h. Half of each tumor and a piece of liver tissue ($100 mg) was then immediately frozen in liquid nitrogen and stored at À80 C for liquid chromatography/tandem mass spectrometry (LC/MS-MS) and CYPOR activity assays. Single cells were prepared from the other half of each tumor, for clonogenic assay and flow cytometry, by mincing and digesting with enzyme cocktail (2.5 mg/mL Pronase, 1 mg/mL collagenase, and 0.2 mg/mL DNAase I) for 30 minutes at 37 C.
CEN-209 and TPZ metabolism
In vitro drug metabolism studies were done using 96-well plates, with log-phase cells harvested by trypsinization and resuspended in aMEM with 5% FCS, 200 mmol/L 2 0 -deoxycytidine and 17 mmol/L D-glucose. Mean cell volume was determined with a Model Z2 Coulter counter (Beckman). Drugs in 10 mL medium were added to 90 mL of cell suspension containing 10 5 cells, with 3 replicates per measurement. The plates were incubated at 37 C under oxic (5% CO 2 incubator) or hypoxic (Coy Pd/H 2 anaerobic chamber; 5% CO 2 /5% H 2 /90% N 2 ). For hypoxic incubations, all plastic ware and medium were preequilibrated in the chamber for 3 or more days to remove residual oxygen (38) . After incubation, plates were transferred to ice, medium was collected, and 200 mL ice-cold methanol containing internal standards (see Supplementary Methods) was added to each well. The methanol extracts were combined with the removed medium and stored at À80 C for LC/MS-MS analysis. For assay of CEN-209 and metabolites in liver and tumor, a tissue processing method described previously (39) was used, except that the frozen pulverized tissue was mixed with an equal volume of formic acid buffer (45 mmol/L, pH 4.5) rather than PBS.
LC/MS-MS assays
Methanol extracts of CEN-209, TPZ, and their metabolites were analyzed using an Agilent 1200 ultra high pressure liquid chromatograph and Agilent 6460 triple quadrupole mass spectrometer with electrospray ionization interface and JetStream inlet technology. Details of the analytical method and its validation are given in Supplementary Methods, Supplementary Tables S1-S4, and Supplementary  Fig. S1 .
C-labeled EF5-binding assay
Intracellular covalent binding of [ 14 C]-EF5 was measured in 96-well microplate cultures by modification of a previous method (27) . Cells were incubated with [
14 C]-EF5 under oxic and hypoxic conditions as for the drug metabolism study above. Plates were then centrifuged (1,000 Â g, 5 minutes) and the medium was discarded. Cells were dislodged using trypsin (100 mL, 37 C for 15 minutes), then 50 mL of cold trichloroacetic acid (TCA, 15% in water) was added, and samples were mixed by pipetting and held on ice for 30 minutes. TCA precipitates were collected onto glass fiber filters (PerkinElmer) using a Harvester 96 system (Tomtec), and unbound EF5 was removed by 5 wash cycles with 1% TCA. Radioactivity on the filters was determined with a Packard 1500 Tri-carb Liquid scintillation Analyzer (GMI).
Flow cytometry
Dual staining of EF5 adducts and phospho-ser139 H2AX (gH2AX) was undertaken using cultured cells or dissociated tumors fixed in 70% ethanol. Cells were incubated in blocking buffer (5% FCS, 0.1% Triton X-100 in PBS) for 30 minutes on ice, then stained with mouse monoclonal anti-gH2AX antibody (Abcam; 1:4,000 dilution, 2 hours at room temperature). An Alexa-488 goat anti-mouse IgG secondary (1:400 dilution, 1 hour at room temperature; InVitrogen) was followed by a Cy5-conjugated mouse monoclonal (Elk3-51; Pennsylvania University) against EF5 adducts (75 mg/mL, overnight at 4 C). Cells were counterstained with 4 0 ,6-diamidino-2-phenylindole (1 mg/mL) and analyzed by flow cytometry using a BD LSR II and BD FACSDiva software. Cells from untreated cultured cells or tumors were used as negative controls for gating EF5 and gH2AX.
CYPOR activity, Western immunoblotting, and immunohistochemistry CYPOR activity in the S9 fraction of cell lysates, tumor, and liver were determined as cyanide-resistant, NADPHdependent reduction of cytochrome c using a minor modification of a reported method (40) . CYPOR protein was detected by Western blotting (36) . Tumor sections were immunostained as described in Supplementary  Fig. S5 .
Statistical analysis
Unless otherwise noted, error estimates are SEM. Statistical significance of differences were determined using 2-tailed Student t tests for comparison of 2 groups and ANOVA/Holm-Sidak for comparison of multiple groups. Relationships between variables were determined using linear regression analysis and evaluated using the coefficient of determination (R 2 ).
Results
EF5 is a CYPOR substrate
The hypoxia-activated prodrug TPZ is known to be a substrate for one-electron reduction by CYPOR under hypoxia (28, 29) . To test whether this enzyme also catalyses reductive activation of the hypoxia probe EF5, we developed a microplate assay to compare covalent binding of [
14 C]-EF5 in 2 parental cell lines (SiHa and HCT116) with their corresponding CYPOR transfectants ( Fig. 1 ). Western blotting confirmed overexpression of CYPOR in the SiHa/CYPOR and HCT116/CYPOR clones (Fig. 1A) . CYPOR enzyme activity was increased 8.5-fold in both these lines, relative to wild-type cells, as determined by NADPH-dependent cytochrome c reduction in S9 preparations ( Fig. S2B ).
CEN-209, like TPZ, is also a CYPOR substrate
The TPZ analogue CEN-209 was previously shown to be metabolized to the corresponding 1-oxide and nor-oxide (see Fig. 2A for structures) in hypoxic HT29 tumor cell cultures, using HPLC (15) . We sought to investigate these chemically stable endproducts of reduction as biomarkers of the free radical intermediate(s) formed by one-electron reduction that are considered responsible for DNA damage and cytotoxicity ( Fig. 2A) . To measure metabolism of these compounds in a 96-well format, we developed a sensitive LC/MS-MS assay (lower limit of quantitation 0.01 mmol/L for CEN-209 and 0.003 mmol/L for its reduced metabolites), as described in Supplementary Methods. This assay was used to confirm the hypoxia-selective formation of the 1-oxide and nor-oxide metabolites in SiHa and HCT116 cells (Fig. 2B) . Importantly, the rate of CEN-209 reduction was increased by approximately 3-fold (2.3-to 4.3-fold, depending on the CEN-209 concentration and chemical species monitored) by overexpression of CYPOR in both cell lines, showing that CEN-209 is a CYPOR substrate. A similar pattern was observed for hypoxic metabolism of TPZ in HCT116 cells, with a 2-to 4-fold increase in its reduction in the CYPOR-overexpressing line, with rates of bioreductive loss of the prodrug approximately 2-fold lower than for CEN-209 ( Supplementary Fig. S3 ).
EF5 binding is a stronger predictor of CEN-209 reduction than is CYPOR activity
Relationships between the reduction of EF5, TPZ, and CEN-209 were extended to a panel of 14 human cancer cell lines, using the above 96-well plate assays to evaluate metabolism of all 3 compounds simultaneously. In each experiment, 6 cell lines, including 2 reference lines (HCT116 and HCT116/CYPOR) for quality control, were tested at 2 drug concentrations (20 and 60 mmol/L [ 14 C]-EF5 for 5 hours; 10 and 30 mmol/L TPZ or CEN-209 for 3 hours) under both oxic and hypoxic conditions. Each condition was tested using 3 technical replicates in 2 to 4 independent experiments. Importantly, reductive metabolism of all 3 compounds was highly suppressed by oxygen in all 14 cell lines ( Supplementary Fig. S4 ), indicating that competing 2-electron reduction is not a significant factor and that the stable end reduction products can therefore be used as biomarkers of the one-electron reduction pathway in cell culture. The minor rates of aerobic reduction were subtracted from the hypoxic values to estimate the oneelectron reduction capacity of each cell line for each substrate.
Across the panel of cell lines, there was an approximately 4-fold range in rates of this one-electron reduction of EF5, TPZ, and CEN-209. The rates for TPZ and CEN-209 were highly correlated (Fig. 3A) , with an R 2 value of 0.87 (P < 0.001), which suggests that the 2 prodrugs are reduced by the same enzymes. CYPOR enzyme activity also varied over an approximately 4-fold range and showed a statistically significant correlation with one-electron metabolism of CEN-209 (Fig. 3B In conclusion, cell line-specific differences in CYPOR activity seem to contribute to differences in one-electron reduction of CEN-209 and TPZ under hypoxia, but EF5 binding is a better predictor of this capacity for hypoxia-selective prodrug metabolism than is CYPOR activity, suggesting that EF5 also interrogates other one-electron reductases capable of activating CEN-209.
Overexpression of CYPOR also increases reductive activation of CEN-209 in tumors
To further investigate the potential of EF5 as a biomarker for CEN-209, we exploited the natural variation in hypoxia and reductase activity between individual HCT116 tumor xenografts. To provide a more robust test, we also compared groups in which these variables were deliberately modified, either by overexpressing CYPOR (xenografts grown from HCT116/CYPOR cells) or by modulating tumor hypoxia using different respiratory gases (10% oxygen, air or HBO). HCT116/CYPOR tumors showed clearly increased (although nonuniform) CYPOR expression by immunostaining ( Supplementary Fig. S5 ), and S9 preparations from these tumors showed 7.2-fold higher CYPOR enzyme activity than WT tumors, although lower than in liver (Fig. 4A) . After dosing tumor-bearing mice with EF5, HCT116/CYPOR tumors had a similar hypoxic fraction to WT tumors (as determined by the proportion of EF5-positive cells by flow cytometry), but the mean fluorescence of EF5-positive cells was higher in HCT116/CYPOR tumors, showing increased reduction of EF5 (Fig. 4B ).
An initial investigation of metabolic reduction of CEN-209 showed a trend to lower concentrations of the prodrug and higher concentrations of the end product (nor-oxide), in CYPOR than WT tumors (Fig. 4C, left) , and a significant increase in the ratio of reduced metabolites in tumor/liver in mice with the CYPOR-overexpressing tumors (Fig. 4C, right) . Levels of the reduced metabolites increased when mice breathed 10% oxygen and decreased when breathing HBO after dosing with CEN-209, both in HCT116/WT tumors and liver (Fig. 4D) , similar to the pattern shown subsequently for EF5 binding (see Fig. 6B ).
gH2AX is a surrogate for clonogenic cell killing by Despite the similarity in CYPOR and hypoxia dependence of EF5 binding and CEN-209 reduction in HCT116 tumors, the extensive hepatic reduction of CEN-209 suggested that systemic circulation of these stable metabolites might complicate their use as biomarkers in tumors. We therefore evaluated whether the DNA damage response to CEN-209 might provide a pharmacodynamic biomarker for local formation of the active cytotoxic free radical. In particular, we examined whether gH2AX can be used as an early pharmacodynamic biomarker that can be investigated on the same timescale as EF5 binding. This hypothesis builds on earlier studies validating gH2AX as a pharmacodynamic biomarker for clonogenic cell killing by TPZ and other clastogenic cytotoxic drugs (41, 42) . Concentrationresponse relationships for gH2AX formation were investigated by flow cytometry 60 minutes after a 1-hour drug exposure, along with clonogenic cell killing in the same experiments, as illustrated for hypoxic SiHa cell suspensions in Fig. 5A and B, respectively. This showed higher potency of CEN-209 relative to either TPZ or the TPZ analogue SN29751 (15) for both endpoints. In these experiments, the potency of SN29751 seemed to be higher than TPZ for gH2AX induction but lower for cell killing, although in additional independent experiments (Fig. 5C ), this difference was not apparent. Overall, under both oxic and hypoxic conditions in SiHa/WT and SiHa/CYPOR cells, there was a strong and highly significant linear relationship (loglog slope 1.02) between potency for both the gH2AX and clonogenic cell killing endpoints (Fig. 5C ).
EF5 binding predicts CEN-209 activation in individual tumor xenografts
To investigate whether EF5 identifies the cells in HCT116 tumors able to activate CEN-209, we dosed mice with EF5 and CEN-209 simultaneously 1.5 hours before excising tumors. Dual staining of EF5 and gH2AX for flow cytometry (illustrated in Supplementary Fig. S6 ) showed that CEN-209 induced gH2AX more effectively in EF5-positive than EF5-negative cells (Fig. 6A) , confirming the selective activation of the bioreductive prodrug in hypoxic regions of the tumors. Furthermore, changing the oxygen concentration breathed by the mice (10% O 2 or HBO) caused similar changes in the proportion of EF5-positive and gH2AX-positive cells (Fig. 6B) . When analyzed at the individual tumor level (Fig. 6C) , these same studies showed a strong (R 2 ¼ 0.68) and highly significant (P < 0.0001) correlation between EF5 binding and gH2AX response to CEN-209. In a separate experiment, we confirmed the suppression of EF5 binding by HBO (Fig. 6D, left panel) and also showed that HBO suppressed clonogenic cell killing of hypoxic cells by CEN-209 (Fig. 6D, right panel) when the drug was administered after irradiation (which was used to sterilize oxic cells). Taken together, these results clearly showed the ability of EF5 to act as a predictive biomarker for the bioreductive activation of CEN-209 to a DNA-damaging, cytotoxic species.
Discussion
Given the marked heterogeneity in tumor hypoxia between patients with the same clinical classification (16) , it is well understood that exploiting hypoxia as a target for therapeutics will require tools for assessing the presence of the target in individual tumors (1, 9). 2-Nitroimidazole probes represent one of the most promising biomarkers for this purpose, especially because of their potential for noninvasive imaging by PET or MRI (22, 43) . This concept is supported by the demonstration that [ 18 F]-EF5 binding predicts radiosensitivity, resulting from hypoxia, in a preclinical model (44) , and that [
18 F]-EF5 binding varies greatly in patients with HNSCC in a manner correlated with tumor perfusion (24) . In addition, immunostaining of bound EF5 has been shown to correlate with outcome in radiotherapy of HNSCC (26) . What is less well appreciated is that there is also significant variation in activity of the one-electron reductases required for activation of 2-nitroimidazole probes and bioreductive prodrugs in hypoxic cells, as shown by variation in metabolismdependent binding of EF5 in biopsy samples of human (26) . This led us to evaluate whether expression of the one-electron reductase CYPOR, previously implicated in bioreductive prodrug activation (28, (30) (31) (32) , might predict hypoxic activation of the novel prodrug CEN-209. We show that CYPOR expression is a weak predictor of CEN-209 reduction in a panel of human tumor cell lines, but that metabolic activation of EF5 is a stronger, highly significant predictor. This dual reporting of both hypoxia and reductase expression commends codevelopment of EF5 as a companion diagnostic in conjunction with CEN-209.
In this study, we focused initially on the stable end products of CEN-209 reduction as biomarkers for its metabolic activation, developing a sensitive LC/MS-MS-based (15) hypoxia-selective metabolism of CEN-209 to its 1-oxide and nor-oxide, and showed that reduction (especially formation of the final 4-electron reduction product) is more rapid than for TPZ (Fig.  2B vs. Supplementary Fig. S3 ). This difference is consistent with the higher reduction potential conferred by the 3-alkyl substituent in CEN-209 (15) . We also adapted an assay for covalent binding of radiolabeled EF5 (27) to a 96-well format and used these assays with cell lines overexpressing CYPOR to show that EF5 and CEN-209 are both substrates for this reductase, as shown previously for TPZ (45, 46 ) and for prototype 2-nitroimidazole hypoxia probes (32) . To identify potential tools for predicting CEN-209 metabolism under hypoxia, we used these assays to compare oneelectron (hypoxia dependent) prodrug activation in a panel of human tumor cell lines. Several technical aspects of these assays warrant comment: First, the 96-well plate format made it feasible to compare metabolism of all 3 compounds using the same cell preparations, minimizing the impact of any variations between experiments. Second, 2 cell lines (HCT116/WT and HCT116/CYPOR) were included for quality control purposes in all experiments; 1 of 10 experiments was rejected because hypoxic EF5 binding in HCT116/CYPOR (interexperiment CV ¼ 27%) was more than 2 SD below the mean. Third, all 3 compounds seem to be high K m substrates for the endogenous reductases, with no evidence of saturation over the concentration range of interest (Figs. 1C, 2B, Supplementary Figs. S1 and S3) , which made it feasible to normalize rates for the input drug concentration to reduce these to a single parameter. For all 3 compounds, these normalized rates were very similar at the lower and higher concentrations tested in the 14 cell line panel, which confirms the validity of the normalization and also gives confidence that the results were not affected by acute cytotoxicity. Fourth, differences in cell size between lines were excluded as a reason for the correlations (which remained highly significant when rates were normalized for cell volume rather than cell number).
A notable feature of these experiments is that little metabolism of any of the compounds was observed under aerobic conditions in any of the cell lines (Supplementary Fig. S4 ). This indicates that CEN-209, like TPZ, is not a facile substrate for oxygen-insensitive 2-electron reductases, such as DT-diaphorase, and (as a corollary) that reduction under hypoxia proceeds almost exclusively via one-electron reduction to the free radical intermediate responsible for cytotoxicity. This justifies use of the difference between the hypoxic and oxic rates as a biomarker for cytotoxic activation in vitro (although we show the stable metabolites are less suitable as biomarkers of reductive activation in mice, given their potential for redistribution between tissues). The finding that hypoxia-selective reductive metabolism of CEN-209 correlates more strongly with EF5 binding than with CYPOR activity across the in vitro cell line panel suggests there are significant additional one-electron reductases in human tumor cell lines. The latter conclusion is also consistent with the greater increase in CYPOR enzyme activity (8.5-fold) than CEN-209, TPZ, or EF5 metabolism (2-to 5-fold), when CYPOR is overexpressed in either HCT116 or SiHa cells (Figs. 1, 2, Supplementary Figs. S1 and S3), indicating that the basal (endogenous) activity includes contribution from other enzymes. This points to the importance of identifying the other reductases, which would potentially allow their molecular profiling in individual tumors (1, 9, 47) . However, given that EF5 shares reductases with CEN-209, it offers the advantage of integrating total enzymatic activity, not just reporting gene expression, across this poorly characterized family of enzymes. Furthermore, as a dual biomarker for hypoxia and reductase activity, EF5 offers the ability to interrogate one-electron reductase activity in the target hypoxic zones of tumors. Indeed, if variation in EF5 binding between tumors reflects differences in reductase activity as well as hypoxia, EF5 may be an even more appropriate diagnostic for CEN-209 than for radiotherapy; low-reductase hypoxic tumors would be misclassified by EF5 as potentially radiosensitive, but correctly classified as CEN-209 insensitive.
Given these encouraging results in cell culture, we went on to show the potential of EF5 as a predictive biomarker for CEN-209 activation in an HCT116 xenograft model. Manipulating reductase activity (by overexpression of CYPOR) and hypoxia (using HBO or 10% oxygen as respiratory gases) within a single genetic background isolated these determinants. We used flow cytometry as an economical alternative to PET imaging for evaluating EF5 binding in these studies, which also avoided partial volume effects and sensitivity limitations in imaging these small tumors. Although we could show CYPOR-and hypoxia-dependent reductive metabolism of CEN-209 in HCT116 tumors ( Fig.  4C and D) , hepatic activation was also hypoxia dependent (Fig. 4D) . When we corrected for differences in systemic metabolism between mice (ratio of reduced metabolites in tumor/liver for individual animals), there was a statistically significant increase in bioreductive metabolism of CEN-209 in CYPOR-overexpressing tumors (Fig. 4C) . However, the potential for redistribution of these stable reduced metabolites from liver and/or other normal tissues to tumor complicates their use as an endpoint for intratumor CEN-209 activation, given the likelihood that extratumor activation will differ between individuals. This led us to evaluate gH2AX as a pharmacodynamic biomarker, which was shown to predict clonogenic cell killing by CEN-209 in vitro when CYPOR and hypoxia were manipulated (Fig. 5) . These results are consistent with earlier studies validating gH2AX as a predictive biomarker for TPZ cytotoxicity (41, 42) .
The CEN-209 gH2AX response was greater in hypoxic (EF5 þ ) than better oxygenated cells (EF5 À ) in HCT116 tumors (Fig. 6A) , although the differential was modest. This is likely to reflect in part that CEN-209 requires less severe hypoxia for its activation than does EF5 (15, 48) , so that some EF5 À cells will activate CEN-209 appreciably. This would not necessarily compromise use of EF5 as a predictive biomarker for CEN-209, provided that moderately hypoxic cells able to activate CEN-209 are typically contiguous with more severely hypoxic regions able to activate EF5. In support of this, altering the oxygen concentration of respiratory gases induced similar changes in the proportion of EF5 þ and gH2AX þ cells in tumors, at both the group level and in individual tumors ( Fig. 6B and C) . The use of flow cytometry to assess EF5 binding (invasively) in this study necessitated use of short-term pharmacodynamic endpoints (DNA damage response and clonogenicity) to assess CEN-209 activation. An earlier preclinical study with TPZ also showed a correlation between EF5 binding and DNA damage in individual tumors using invasive methods (49) . In contrast, [ 18 F]-EF5 PET imaging offers the potential for noninvasive monitoring of reductases and hypoxia and would make it possible to evaluate more clinically relevant tumor response endpoints. We also note the potential use of [ 18 F]-EF5 PET imaging as an early response biomarker for CEN-209, which has shown promise in initial preclinical studies (50) .
This study confirms close similarities in the pharmacology of CEN-209 and TPZ, with analogous reduction products, similar reductase specificities, and the same relationships between gH2AX induction and clonogenic cell killing. Coupled with the previous demonstration that these agents have similar cell line dependence of cytotoxicity and quantitative oxygen dependence (15) , and recent studies showing similar DNA repair pathway dependence (51), these findings indicate that clinical development of CEN-209 can take advantage of experience with TPZ. Perhaps of paramount importance is the need to use hypoxic imaging as a stratification biomarker, the case for which is already supported by a provocative clinical study with TPZ (18) and which is further strengthened by the present demonstration that 2-nitroimidazole PET probes can act as dual reporter for reductase activity as well as hypoxia. 
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